Adverum, formerly Avalanche Biotechnologies, is a biotechnology company developing gene therapies for patients living with rare diseases and diseases of the eye that is headquartered in Menlo Park, California and was founded in 2006 by Mark S. Blumenkranz, Mitchell H. Finer, Steven D. Schwartz, and Thomas W. Chalberg. The company officially became Adverum Biotechnologies in May, 2016 after the merger of Avalanche Biotechnologies and Annapurna Therapeutics.
On November 22, 2013 Adverum Biotechnologies completed a venture capital round raising $5.7 million in capital from undisclosed investors.
On April 22, 2014 Adverum Biotechnologies completed their series B funding round with $55 million in capital from Venrock (lead investor), Sabby Capital, Rock Springs Capital, Redmile Group, Deerfield, and Adage Capital management.
On September 7, 2014 Adverum Biotechnologies completed their second venture capital round with $10 million in funding from undisclosed investors.
Timeline
The company officially became Adverum Biotechnologies in May, 2016 after the merger of Avalanche Biotechnologies and Annapurna Therapeutics.
On September 7, 2014 Adverum Biotechnologies completed their second venture capital round with $10 million in funding from undisclosed investors.
On April 22, 2014 Adverum Biotechnologies completed their series B funding round with $55 million in capital from Venrock (lead investor), Sabby Capital, Rock Springs Capital, Redmile Group, Deerfield, and Adage Capital management.
On November 22, 2013 Adverum Biotechnologies completed a venture capital round raising $5.7 million in capital from undisclosed investor
People
Mark S. Blumenkranz
Co-Founder
Carla Fiankan
Vice President, Regulatory Affairs
Claire Gelfman
Executive Director, Pharmaceutical Development
Jennifer Cheng
Vice President and General Council
Leone Patterson
CEO, Director, and CFO
Mehdi Gasmi
President and CSO
Michael Steel
Vice President, Quality
Mike Fitzgerald
Vice President , Human Resources
Mitchell H. Finer
Co-Founder
Pratik Jaluria
Executive Director, Process Development and Manufacturing
Steven D. Schwartz
Co-Founder
Thomas W. Chalberg
Co-Founder
Further reading
Avalanche Biotechnologies Agrees to Buy Annapurna Therapeutics
Genenews
Web
Here's Why Adverum Biotechnologies Dropped as Much as 42.4% Today
Maxx Chatsko
Web
